Rose C, Waksal H, Goldstein N I
Department of Immunology/Monoclonal Antibodies, ImClone Systems Inc., New York, New York 10014.
Hybridoma. 1994 Jun;13(3):221-7. doi: 10.1089/hyb.1994.13.221.
Small cell lung carcinoma (SCLC) represents about 25% of all lung cancers. Human SCLC shows neuroendocrine features such as the production of neural peptide hormones, marker enzymes and neurosecretory granules, and the expression of neural cell adhesion molecules (NCAMs). Although SCLC is sensitive to both chemotherapy and radiation, prognosis remains poor due to the appearance of post-treatment chemo- and radioresistant variants. Monoclonal antibodies (MAbs) have been developed that bind to SCLC tumor antigens. We have used similar technology to define another SCLC marker designated gP94/115. The MAb CR101 binds to a highly glycosylated, cell-surface antigen associated with SCLC. In vitro expression of the antigen appears to be restricted to cell lines of SCLC origin. Enzymatic removal of the sugars resolves the antigen into two proteins of 94 and 115 kD by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Fluorescence-activated cell sorting (FACS) analysis confirms the antibody's specificity. These results indicate that CR101 may recognize a novel protein expressed by SCLC.
小细胞肺癌（SCLC）约占所有肺癌的25%。人类小细胞肺癌表现出神经内分泌特征，如神经肽激素、标记酶和神经分泌颗粒的产生，以及神经细胞黏附分子（NCAM）的表达。尽管小细胞肺癌对化疗和放疗均敏感，但由于治疗后出现化疗和放疗抗性变体，其预后仍然很差。已经开发出了与小细胞肺癌肿瘤抗原结合的单克隆抗体（MAb）。我们使用了类似的技术来确定另一种名为gP94/115的小细胞肺癌标志物。单克隆抗体CR101与一种与小细胞肺癌相关的高度糖基化的细胞表面抗原结合。该抗原的体外表达似乎仅限于小细胞肺癌来源的细胞系。通过十二烷基硫酸钠-聚丙烯酰胺凝胶电泳（SDS-PAGE），酶法去除糖类可将该抗原分解为94 kD和115 kD的两种蛋白质。荧光激活细胞分选（FACS）分析证实了该抗体的特异性。这些结果表明，CR101可能识别一种由小细胞肺癌表达的新型蛋白质。
